Search for
Fibroid Large biopsy 3-6 cm
Biopsy
Report in 240Hrs
At Home
No Fasting Required
Details
Uterine fibroid histology.
₹666₹951
30% OFF
Fibroid Large Biopsy 3-6 cm - Comprehensive Medical Test Information Guide
- Why is it done?
- Purpose: This procedure involves tissue sampling of fibroid tumors measuring 3-6 cm in diameter to obtain histological diagnosis and determine benign vs malignant pathology
- Primary indications: Evaluation of fibroids with imaging characteristics suspicious for malignancy, monitoring rapidly growing fibroids, assessment of leiomyosarcoma risk, and confirmation of benign leiomyoma diagnosis
- Clinical circumstances: Performed when imaging findings are indeterminate, fibroids cause abnormal uterine bleeding, patient experiences pelvic pain or pressure, or when fertility preservation requires accurate diagnosis
- Typical timing: Generally performed after imaging studies confirm fibroid presence and when clinical symptoms warrant tissue diagnosis or when ultrasound/MRI findings raise concern for malignant transformation
- Normal Range
- Normal/Benign finding: Histopathological confirmation of benign smooth muscle tumor (leiomyoma) with organized smooth muscle cells, normal mitotic figures (less than 5 mitoses per 10 high-power fields), and absence of cellular atypia or necrosis
- Reference findings: Mature fibroid tissue characterized by well-circumscribed spindle cell proliferation without encapsulation, absence of hemorrhage or extensive degeneration, and no evidence of cellular pleomorphism
- Measurement criteria: Biopsy specimen measuring adequate size (typically 3-6 cm as indicated) with sufficient cellularity for diagnostic evaluation and proper tissue preservation
- Interpretation: Negative/Normal = Benign leiomyoma, no malignancy; Positive/Abnormal = Leiomyosarcoma, atypical variants, or other malignant pathology requiring immediate intervention
- Interpretation
- Benign Leiomyoma (Low Risk): Demonstrates typical smooth muscle differentiation with organized fascicles, low mitotic activity (0-4 per 10 HPF), absence of significant atypia, normal cell borders, and benign clinical course expected
- Atypical Leiomyoma (Intermediate Risk): Shows moderate cellular atypia, increased mitotic figures (5-9 per 10 HPF), cytologic enlargement, or borderline features requiring close clinical follow-up and potential adjuvant therapy consideration
- Leiomyosarcoma (High Risk): Characterized by marked cellular atypia, brisk mitotic activity (≥10 per 10 HPF), tumor necrosis, cellular pleomorphism, vascular invasion, or coagulative necrosis indicating malignant transformation
- Factors affecting results: Age of patient, hormonal status, prior radiation exposure, neurofibromatosis type 1 association, immunohistochemical markers (desmin, smooth muscle actin, p53), and molecular testing for genetic alterations
- Clinical significance: Results directly inform treatment planning, determine need for hysterectomy vs conservative management, guide surveillance intervals, influence reproductive counseling, and establish prognosis for long-term outcomes
- Associated Organs
- Primary organ: Uterus (myometrium) - fibroids originate from smooth muscle layer; biopsy evaluates uterine pathology directly
- Associated organ systems: Female reproductive system (ovaries, fallopian tubes affected by mass effect), pelvic structures (bladder, rectum compressed by large fibroids), and vascular system (blood supply involvement)
- Common associated conditions: Abnormal uterine bleeding, secondary anemia, infertility, recurrent miscarriage, dysmenorrhea, dyspareunia, urinary frequency/urgency, bowel dysfunction, and pelvic pain syndrome
- Diseases diagnosed/monitored: Benign leiomyoma (uterine fibroids), leiomyosarcoma (malignant uterine sarcoma), atypical smooth muscle tumors, and potential metastatic disease to pelvic/abdominal organs
- Potential complications: Hemorrhage requiring transfusion, perforation of uterine wall, infection/endometritis, bowel or bladder injury, venous thromboembolism, and sepsis in severe cases
- Long-term risks if malignancy identified: Tumor recurrence, metastatic spread to lungs/liver/peritoneum, compromised reproductive function, and systemic complications from advanced sarcoma
- Follow-up Tests
- If benign leiomyoma confirmed: Pelvic ultrasound every 6-12 months for size monitoring, CBC to assess for anemia from bleeding, clinical symptom evaluation at routine gynecologic visits
- If atypical leiomyoma identified: Repeat imaging with MRI for comprehensive assessment, immunohistochemical staining (p53, Ki-67) for malignancy markers, molecular testing for genetic mutations, gynecologic oncology referral
- If leiomyosarcoma diagnosed: Urgent staging CT chest/abdomen/pelvis for metastatic disease, gynecologic oncology consultation, consideration of hysterectomy/bilateral salpingo-oophorectomy, possible chemotherapy regimen initiation
- Complementary diagnostic tests: Flow cytometry for ploidy analysis, electron microscopy for ultrastructural evaluation, FISH testing for genetic abnormalities, and gene expression profiling for risk stratification
- Monitoring frequency: Benign = annually; Atypical = every 3-6 months; Malignant = post-treatment surveillance imaging every 3-4 months for first 2 years, then every 6 months for additional 3 years
- Laboratory tests: Complete metabolic panel, liver/kidney function tests, tumor markers (LDH for sarcoma), and coagulation studies if surgical intervention planned
- Fasting Required?
- Fasting requirement: Yes - typically 6-8 hours of fasting required if biopsy performed under general or regional anesthesia; NPO (nothing by mouth) status from midnight or 4-6 hours prior to scheduled procedure
- Duration and specifications: 6-8 hours for solid foods, 2-4 hours for clear liquids, exact timing determined by anesthesia provider based on procedure type (hysteroscopic, transvaginal ultrasound-guided, or open surgical biopsy)
- Medications to continue: Continue regular antihypertensive and cardiac medications with minimal sips of water; Hold anticoagulants (warfarin, aspirin, NSAID) as directed by physician 5-7 days prior; Continue diabetic medications per anesthesia protocol
- Medications to avoid: Discontinue anticoagulants/antiplatelet agents per institutional protocol; Hold herbal supplements (ginkgo, ginger, ginseng) 1 week prior; Avoid NSAIDs 3-5 days before procedure; Do not take metformin day of procedure
- Pre-procedure preparation: Complete pre-operative laboratory work (CBC, coagulation studies, metabolic panel), obtain signed informed consent, verify patient identification, empty bladder immediately before procedure, and remove all jewelry/piercings
- Additional instructions: Arrange for responsible adult transportation home (sedation effects last 24 hours); Avoid strenuous activity for 24-48 hours post-procedure; Monitor for vaginal bleeding, fever, severe cramping, or signs of infection; Schedule post-operative follow-up within 1-2 weeks
How our test process works!
